Experimental drug ravulizumab tested for kidney inflammation

NCT ID NCT04564339

Terminated Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tested the drug ravulizumab (Ultomiris) in 123 adults with lupus nephritis or IgA nephropathy, two conditions that cause kidney inflammation. Participants received either ravulizumab or a placebo alongside standard care. The study aimed to see if the drug could reduce protein in the urine, a sign of kidney damage. However, the trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ravulizumab (Ultomiris)
What this could lead to: If successful, this could point toward a new treatment option for kidney inflammation in lupus and IgA nephropathy.
What could go wrong: The trial was terminated early, so results are limited. It is a small Phase 2 study, and the drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glomerulonephritis IgA glomerulonephritis lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOGLOBULIN A NEPHROPATHY LUPUS NEPHRITIS

Contacts and locations

Locations

Research Site

San Dimas, California, 91773, United States
Research Site

Santa Monica, California, 90404, United States
Research Site

South Gate, California, 90280, United States
Research Site

Stanford, California, 94305, United States
Research Site

Orlando, Florida, 32835, United States
Research Site

Plantation, Florida, 33324, United States
Research Site

Lawrenceville, Georgia, 30046, United States
Research Site

Lexington, Kentucky, 40536, United States
Research Site

Louisville, Kentucky, 40202, United States
Research Site

Boston, Massachusetts, 02114, United States
Research Site

Boston, Massachusetts, 02115, United States
Research Site

Kansas City, Missouri, 64111, United States
Research Site

New York, New York, 10003, United States
Research Site

Chapel Hill, North Carolina, 27599, United States
Research Site

Columbus, Ohio, 43203, United States
Research Site

El Paso, Texas, 79935, United States
Research Site

Houston, Texas, 77054, United States
Research Site

Herston, 4029, Australia
Research Site

Parkville, 3050, Australia
Research Site

Westmead, 2145, Australia
Research Site

London, Ontario, N6A 5W9, Canada
Research Site

Montreal, Quebec, H1T 2M4, Canada
Research Site

Québec, Quebec, G1R 2J6, Canada
Research Site

Clermont-Ferrand, 63003, France
Research Site

Le Kremlin-Bicêtre, 94270, France
Research Site

Paris, 75020, France
Research Site

Saint-Priest-en-Jarez, 42270, France
Research Site

Strasbourg, 67091, France
Research Site

Toulouse, 31059, France
Research Site

Berlin, 10117, Germany
Research Site

Essen, 45147, Germany
Research Site

Hanover, 30625, Germany
Research Site

Lübeck, 23538, Germany
Research Site

Bologna, 40138, Italy
Research Site

Brescia, 25123, Italy
Research Site

Florence, 50134, Italy
Research Site

Torino, 10154, Italy
Research Site

Maastricht, 6229 HX, Netherlands
Research Site

Lodz, 92-213, Poland
Research Site

Anyang-si, 14068, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 134-727, South Korea
Research Site

Seoul, 6591, South Korea
Research Site

Barcelona, 08035, Spain
Research Site

Barcelona, 08036, Spain
Research Site

Lleida, 25198, Spain
Research Site

Madrid, 28007, Spain
Research Site

Madrid, 28040, Spain
Research Site

Madrid, 28041, Spain
Research Site

Málaga, 29010, Spain
Research Site

Palma de Mallorca, 07010, Spain
Research Site

Seville, 41013, Spain
Research Site

Valencia, 46017, Spain
Research Site

Zaragoza, 50009, Spain
Research Site

Kaohsiung City, 80756, Taiwan
Research Site

Kaohsiung City, 833401, Taiwan
Research Site

New Taipei City, 23561, Taiwan
Research Site

Taichung, 40447, Taiwan
Research Site

Edgbaston, B15 2WB, United Kingdom
Research Site

London, SE1 7EH, United Kingdom
Research Site

London, W12 0HS, United Kingdom
Research Site

Salford, M6 8HD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.